Drug-induced long QT and torsade de pointes: recent advances
暂无分享,去创建一个
[1] D. Roden,et al. Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome. , 2008, Journal of the American College of Cardiology.
[2] D. Roden,et al. P1-22: Persistent atrial fibrillation is associated with reduced risk of Torsades de Pointes in patients with drug-induced long QT syndrome , 2006 .
[3] Hua-rong Lu,et al. Calmodulin Antagonist W‐7 Prevents Sparfloxacin‐Induced Early Afterdepolarizations (EADs) in Isolated Rabbit Purkinje Fibers: Importance of Beat‐to‐Beat Instability of the Repolarization , 2006, Journal of cardiovascular electrophysiology.
[4] M. Sanguinetti,et al. hERG potassium channels and cardiac arrhythmia , 2006, Nature.
[5] C. January,et al. Most LQT2 Mutations Reduce Kv11.1 (hERG) Current by a Class 2 (Trafficking-Deficient) Mechanism , 2006, Circulation.
[6] P. Schwartz. The congenital long QT syndromes from genotype to phenotype: clinical implications , 2006, Journal of internal medicine.
[7] D. Roden. Long QT syndrome: reduced repolarization reserve and the genetic link , 2006, Journal of internal medicine.
[8] P. C. Viswanathan,et al. New Mechanism Contributing to Drug-Induced Arrhythmia: Rescue of a Misprocessed LQT3 Mutant , 2005, Circulation.
[9] Charles Antzelevitch,et al. Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes. , 2005, Heart rhythm.
[10] J. Turgeon,et al. Drug-induced long QT syndrome and torsade de pointes. , 2005, The Canadian journal of cardiology.
[11] P. C. Viswanathan,et al. Genetics of acquired long QT syndrome. , 2005, The Journal of clinical investigation.
[12] Jun Zhou,et al. Pentamidine reduces hERG expression to prolong the QT interval , 2005, British journal of pharmacology.
[13] G. Salama,et al. Sex Modulates the Arrhythmogenic Substrate in Prepubertal Rabbit Hearts with Long QT 2 , 2005, Journal of cardiovascular electrophysiology.
[14] A. Arya. Gender‐Related Differences in Ventricular Repolarization: Beyond Gonadal Steroids , 2005, Journal of cardiovascular electrophysiology.
[15] M. Holm,et al. In vivo validation of the coincidence of the peak and end of the T wave with full repolarization of the epicardium and endocardium in swine. , 2005, Heart rhythm.
[16] D. Roden,et al. Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. , 2005, Heart rhythm.
[17] K. Sunagawa,et al. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. , 2005, Journal of the American College of Cardiology.
[18] Y. Kuryshev,et al. Pentamidine-Induced Long QT Syndrome and Block of hERG Trafficking , 2005, Journal of Pharmacology and Experimental Therapeutics.
[19] M. Grabowski,et al. Drug-Induced Long-QT Syndrome With Macroscopic T-Wave Alternans , 2004 .
[20] Milan Stengl,et al. Increased Short-Term Variability of Repolarization Predicts d-Sotalol–Induced Torsades de Pointes in Dogs , 2004, Circulation.
[21] K. Murray,et al. Relationship between area deprivation and the anticaries benefit of an oral health programme providing free fluoride toothpaste to young children. , 2004, Community dentistry and oral epidemiology.
[22] S. Chism,et al. Drug-induced long QT syndrome and Torsade de Pointes. , 2004, The Journal of the Arkansas Medical Society.
[23] Gregory W. Kauffman,et al. Physicochemical Features of the hERG Channel Drug Binding Site* , 2004, Journal of Biological Chemistry.
[24] H. Mabuchi,et al. T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. , 2003, Clinical science.
[25] J. Mason,et al. A new oral therapy for long QT syndrome: long-term oral potassium improves repolarization in patients with HERG mutations. , 2003, Journal of the American College of Cardiology.
[26] Li Zhang,et al. Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. , 2003, Journal of the American College of Cardiology.
[27] C. January,et al. Pharmacological Rescue of Human K+ Channel Long-QT2 Mutations: Human Ether-a-Go-Go-Related Gene Rescue Without Block , 2002, Circulation.
[28] P. C. Viswanathan,et al. Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes , 2002, Circulation.
[29] Jeffrey R. Balser,et al. A sensitive mechanism for cation modulation of potassium current , 2000, Nature Neuroscience.
[30] D. Roden,et al. Exaggerated QT prolongation after cardioversion of atrial fibrillation. , 1999, Journal of the American College of Cardiology.
[31] C. January,et al. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. , 1999, Circulation research.
[32] C. Antzelevitch,et al. Cellular and ionic basis for T-wave alternans under long-QT conditions. , 1999, Circulation.
[33] D. Roden,et al. Normalization of acquired QT prolongation in humans by intravenous potassium. , 1997, Circulation.
[34] D M Roden,et al. Rapid inactivation determines the rectification and [K+]o dependence of the rapid component of the delayed rectifier K+ current in cardiac cells. , 1997, Circulation research.
[35] D. Roden,et al. Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. , 1996, Circulation.
[36] K Shimomura,et al. Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. , 1995, Journal of the American College of Cardiology.
[37] E. Green,et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome , 1995, Cell.
[38] M. Lehmann,et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs , 1993 .
[39] M. Lehmann,et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. , 1993, JAMA.
[40] R. Prineas,et al. Sex differences in the evolution of the electrocardiographic QT interval with age. , 1992, The Canadian journal of cardiology.
[41] R. Woosley,et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin , 1992, Clinical pharmacology and therapeutics.
[42] R. Lazzara. Amiodarone and torsade de pointes. , 1989, Annals of internal medicine.
[43] D. Roden,et al. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. , 1986, American heart journal.
[44] G. Kay,et al. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. , 1983, Journal of the American College of Cardiology.